NEW YORK (GenomeWeb) – Sophia Genetics said today that it has received CE-IVD designation for its Solid Tumor Solution (STS) molecular diagnostic application.
Sophia STS was designed to detect and characterize genomic alterations in 42 clinically relevant genes related to various solid tumors across multiple types of cancer, the Lausanne, Switzerland-based company said. The application runs on top of the Sophia AI artificial intelligence platform.
According to Sophia, STS can detect single-nucleotide variants, insertions and deletions, and gene amplification events. It also can identify microsatellite instability status in six loci associated with colorectal cancer.
"It is designed to maximize diagnostic yield and guide treatment and management decisions," Gioia Althoff, senior vice president for genomics at Sophia Genetics, said in a statement.
Jose López, head of the molecular biology laboratory at the Instituto Valenciano de Oncología in Valencia, Spain, added that STS has helped the cancer center streamline its genomic testing workflow.
"With the STS, our lab has access to a comprehensive solution that accurately detects clinically relevant genomic alterations associated with solid tumors, accelerating the clinicians’ ability to diagnose patients and deliver the best treatment options," he said.